Sterilization is mandatory, non-discretionary manufacturing infrastructure for medtech and pharma. Once a device/drug process is validated with Sterigenics or Nelson Labs, switching requires regulatory requalification — a genuine moat. Not bioprocess per se, but serves the same customers at the same mandatory step.
Conviction○○○○○0 of 5
Research target—Snapshot target
Thesis statusACTIVE_RESEARCHLast reviewed Not reviewed
Market cap$5.11BSnapshot value
Medtech procedure volume recovery driving sterilization demand, Annex 1 RTU conversion increasing single-use sterilization needs, Nordion Cobalt-60 supply chain stability, Nelson Labs testing volume growth from BIOSECURE reshoring
1. EPA ethylene oxide restrictions force costly facility changes. 2. Customer in-housing of sterilization (large medtech builds captive capacity). 3. Cobalt-60 supply disruption (geopolitical — Russian supply). 4. Medtech procedure volume structural decline. 5. Sterilization technology disruption (X-ray, NO2 alternatives).
Low retail interest — boring industrial healthcare services. Institutional-heavy (90%).
Snapshot · Not reviewedNo positioning snapshot available.
Snapshot · Not reviewed